Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.

Spyre Therapeutics, Inc. Common Stock

Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.

	Dec '21	Dec '22	Dec '23
net income	-65.80M -	-83.81M 27.38%	-338.79M 304.21%
depreciation and amortization	1.58M -	1.57M 0.57%	744K 52.52%
deferred income tax	548K -	-327K 159.67%	214.90M 65,817.13%
stock based compensation	8.04M -	7.11M 11.53%	25.68M 261.06%
change in working capital	1.83M -	-5.50M 400.22%	-5.21M 5.40%
accounts receivables		440K -	375K 14.77%
inventory		-440K -	-375K 14.77%
accounts payables	1.06M -	-2.64M 347.98%	218K 108.25%
other working capital	768K -	-2.86M 472.66%	-5.42M 89.52%
other non cash items	90K -	823K 814.44%	2.77M 236.82%
net cash provided by operating activities	-53.72M -	-80.14M 49.20%	-99.91M 24.66%
investments in property plant and equipment	-573K -	-38K 93.37%
acquisitions net			3.04M -
purchases of investments	-133.08M -	-39.50M 70.32%	-166.80M 322.29%
sales maturities of investments	111.03M -	96.55M 13.05%	39.90M 58.67%
other investing activites			15.47M -
net cash used for investing activites	-22.62M -	57.01M 352.04%	-108.39M 290.14%
debt repayment	-510K -	-418K 18.04%	-16K 96.17%
common stock issued	1.90M -	42.87M 2,152.97%	169.11M 294.43%
common stock repurchased
dividends paid
other financing activites			-5.79M -
net cash used provided by financing activities	1.39M -	42.68M 2,963.75%	361.08M 746.05%
effect of forex changes on cash	-15K -	-106K 606.67%	25K 123.58%
net change in cash	-74.96M -	19.44M 125.93%	152.80M 686.16%
cash at beginning of period	91.94M -	16.98M 81.53%	36.42M 114.46%
cash at end of period	16.98M -	36.42M 114.46%	189.22M 419.59%
operating cash flow	-53.72M -	-80.14M 49.20%	-99.91M 24.66%
capital expenditure	-573K -	-38K 93.37%
free cash flow	-54.29M -	-80.18M 47.69%	-99.91M 24.60%

SYRE

COM:SPYRE

Spyre Group

Last Close

27.00

22/11 21:00

Market Cap

1.40B

Beta: -

Volume Today

793.23K

Avg: -

Preview